Organon & Co | OGN - Interest Expense On Debt


Organon & Co reported $111M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Bristol-Myers Squibb USD 411M 21M Mar/2026
Celltrion KRW 19B 1.96B Jun/2025
Cspc Pharmaceutical CNY 6.76M 3.43M Dec/2025
Deva Holding AS TRY 272.53M 69.04M Sep/2023
Dianthus Therapeutics USD 4.44M 263K Sep/2024
Divis Laboratories Ltd INR 60M 0 Mar/2026
Gilead Sciences USD 240M 15M Mar/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
Kangmei Pharma CNY 1.82M 150K Sep/2025
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Laboratorios Farma EUR 699K 666.2K Jun/2025
Medical Developments International AUD 18K 3K Jun/2025
Merck USD 479M 67M Mar/2026
Neuren Pharmaceuticals AUD 0 0 Jun/2024
Novartis USD 281M 8M Sep/2025
Organigram Holdings CAD 179K 127K Mar/2025
Organon & Co USD 111M 17M Mar/2026
Ovoca Bio EUR 7K 6K Jun/2022
Pharma Mar EUR 117K 1.24M Sep/2025
Qiagen NV USD 10.14M 1.92M Dec/2025
Sartorius EUR 49.5M 8.1M Sep/2025
Sino Biopharmaceutical CNY 76.87M 114.23M Jun/2024
Tilray USD 6.7M 2.73M Jun/2025
Zealand Pharma A/S 7.07M 74K Dec/2025